Compare Expensify Inc (EXFY) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Repligen Corporation Common Stock — how do they compare? Expensify Inc trades at $2.44 (market cap $222.95M), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 50× Expensify Inc's market cap, and Expensify Inc is more actively traded (293,722 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Repligen Corporation Common Stock for 0 Days on average.
| EXFY | RGEN | |
|---|---|---|
Market Cap | $222.95M | $11.14B |
Volume | 293,722 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $2.72 | $194.57 |
52-Week Low | $0.75 | $102.87 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | $162.57M | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.45, showing modest daily gains of 0.41%. The stock exhibits a bullish technical signal with strong moving average support. Fundamentally, the company maintains solid revenue around $142M but faces profitability challenges with negative net margins. Recent quarterly earnings show mixed results with two beats and one miss. Analyst sentiment leans positive with a 50% buy rating and $13.75 consensus price target, representing significant upside potential from current levels.
EXFY presents a high-risk, high-reward opportunity with substantial analyst upside but persistent profitability concerns. The company's expansion into European markets and AI integrations provide growth catalysts, though negative earnings and cash flow volatility remain key risks. Investors should weigh the significant price target premium against the company's ongoing transition to profitability.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
